000963 Huadong Medicine
- 34.83
- -0.48-1.36%
About Huadong Medicine Company
The company was founded in 1993 and listed on the Shenzhen Stock Exchange in December 1999. After more than 20 years of development, the company's business covers the entire pharmaceutical industry chain, with the pharmaceutical industry as the lead, while expanding the pharmaceutical business, medical and aesthetic industry, and industrial microbiology business. It has developed into a large-scale comprehensive pharmaceutical listed company integrating pharmaceutical R&D, production and distribution. The company's business covers the entire pharmaceutical industry chain and has four major business segments: pharmaceutical industry, pharmaceutical commerce, medical aesthetics, and industrial microbiology. The company's main products are the pharmaceutical industry sector, the industrial microbiology sector, the pharmaceutical business sector, and the medical and aesthetic business sector. Corporate honors: Shenzhen Stock Exchange China Securities ESG rating AAA, WINDESG rating A, and won the “Top 100 Chinese Listed Companies ESG” by the Securities Times in the 17th China Listed Company Value; ranked 358 in the “Fortune” China 500 in the 14th year; won the “2023 China Top 500 Private Enterprises” and “2023 China's Top 500 Private Enterprises” by the All-China Federation of Industry and Commerce; Selected as the “2022 China Pharmaceutical Industry Top 100” series list; won the 2022 China Pharmaceutical Industry Top 10” “2023 Top 20 Chinese Pharmaceutical Listed Companies with Competitiveness”, Huaxia Times's “2023 Top Ten Innovative Pharmaceutical Companies”; listed on the “2023 China Drug Research and Development Comprehensive Strength Ranking TOP100” and “2023 China Pharmaceutical R&D Strength Ranking TOP100”, etc.
Company Profile
Company Executives
- Name
- Position
- Salary
- liang lv
- Chairman, Directors, General Manager, Chairman of the Strategy Committee, Member of the Remuneration and Assessment Committee
- 2.40M
- wei kang
- Directors, Audit Committee Member, Nomination Committee Members
- 30.00K
- bo ye
- directors, Member of the Sustainability (ESG) Committee
- 30.00K
- liang zhu
- Directors
- 650.00K
- feipeng zhu
- directors, Chairman of the Sustainability (ESG) Committee
- 30.00K
- yang wang
- Directors, Strategy Committee Member
- 13.60K
- ruwei wang
- Independent Directors, Audit Committee Member, Strategy Committee Member, Chairman of the Remuneration and Assessment Committee
- 100.00K
- xiangdong gao
- Independent directors, Member of the Sustainability (ESG) Committee, Chairman of the Nomination Committee, Member of the Remuneration and Assessment Committee
- 100.00K
- jian huang
- Independent Directors, Chairman of the Audit Committee, Nomination Committee Members
- 65.20K
- bo chen
- Board Secretary
- 1.30M
- shufen hu
- Securities Affairs Representative
- --
- xinhua bai
- Chairman of the Supervisory Board, Auditors
- 30.00K
- yanwu zhou
- Auditors
- 30.00K
- yun qin
- Auditors
- 30.00K
- jiqin dong
- Auditors
- 30.00K
- hui wu
- Deputy General Manager
- 1.40M
- jianfei zhang
- Deputy General Manager
- 1.40M
- li zhu
- Deputy General Manager
- 1.40M
- renbo qiu
- Head of Finance
- 1.30M
- jing xia
- Employee Supervisors
- --
- zhifeng xu
- Employee Supervisors
- 650.00K
Analysis
Price Target
No Data
No Data